Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib vs Sunitinib in Advanced Renal Cell Cancer
NCT01024920Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2009
- Primary completion
- Nov 2011
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 5
01
Overview
A Phase 2 trial of nintedanib in renal cell carcinoma (RCC), sponsored by Boehringer Ingelheim. Started Dec 2009; status: completed.
02
Drugs
nintedanib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT01024920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01024920.